BioAffinity Technologies Sees Accelerating Growth Of Physician Practices Ordering CyPath Lung Tests
BioAffinity Technologies Sees Accelerating Growth Of Physician Practices Ordering CyPath Lung Tests
BioAffinity Technologies看到醫生處方CyPath肺部檢測的增長加速
Sales of CyPath Lung tests, onboarding of pathology practices ahead of forecasts
超越預期的CyPath肺部檢測銷售，病理實踐的接入
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today reported 139% growth in the number of pulmonology practices and physicians offering CyPath Lung to patients since Jan. 1, 2024. CyPath Lung is a noninvasive test to detect early-stage lung cancer.
生物技術公司bioAffinity Technologies, Inc.（納斯達克股票代碼：BIAF、BIAFW）專注於早期癌症和肺病的非侵入性檢測需求，今天報告稱，自2024年1月1日以來，使用CyPath肺部檢測的肺部科學實踐和醫生數量增長了139%。CyPath Lung是一種非侵入性檢測方法，用於檢測早期肺癌。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。